Polyrizon Ltd. (PLRZ)
NASDAQ: PLRZ · Real-Time Price · USD
13.15
+0.34 (2.70%)
At close: Aug 28, 2026, 4:00 PM EDT
12.95
-0.20 (-1.48%)
After-hours: Aug 28, 2026, 5:42 PM EDT
Polyrizon Employees
As of December 31, 2025, Polyrizon had 4 total employees, including 2 full-time and 4 part-time employees. The number of employees decreased by 2 or -33.33% compared to the previous year.
Employees
4
Change (1Y)
-2
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$833,750
Market Cap
24.61M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 4 | -2 | -33.33% | 2 | 2 |
| Dec 31, 2024 | 6 | - | - | 2 | 4 |
Related Stocks
| Company Name | Employees |
|---|---|
| Evaxion | 46 |
| Enlivex | 34 |
| Cerenome | 28 |
| Jasper Therapeutics | 22 |
| Quantum BioPharma | 17 |
| Atossa Therapeutics | 16 |
| Lantern Pharma | 16 |
| Tvardi Therapeutics | 12 |
PLRZ News
- 9 days ago - Polyrizon completes clinical site network for NASARIX study - TheFly
- 9 days ago - Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment - GlobeNewsWire
- 2 months ago - Polyrizon announces results from Nasarix biocompatibility evaluation program - TheFly
- 2 months ago - Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial - GlobeNewsWire
- 2 months ago - Polyrizon receives central IRB approval for Nasarix - TheFly
- 2 months ago - Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial - GlobeNewsWire
- 2 months ago - Polyrizon gets patent for Trap & Target mucoadhesive polymer technology platform - TheFly
- 2 months ago - Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform - GlobeNewsWire